PL367828A1 - Środek terapeutyczny - Google Patents

Środek terapeutyczny

Info

Publication number
PL367828A1
PL367828A1 PL02367828A PL36782802A PL367828A1 PL 367828 A1 PL367828 A1 PL 367828A1 PL 02367828 A PL02367828 A PL 02367828A PL 36782802 A PL36782802 A PL 36782802A PL 367828 A1 PL367828 A1 PL 367828A1
Authority
PL
Poland
Prior art keywords
therapeutic agent
hiv
hla
antibodies
injection
Prior art date
Application number
PL02367828A
Other languages
English (en)
Other versions
PL216741B1 (pl
Inventor
Angus G. Dalgleish
Martin J. Cadogan
Jonathan Heeney
Stanley D.T. White
Original Assignee
Aimsco Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0116151A external-priority patent/GB0116151D0/en
Priority claimed from GB0128638A external-priority patent/GB0128638D0/en
Priority claimed from GBGB0201896.8A external-priority patent/GB0201896D0/en
Priority claimed from GB0207509A external-priority patent/GB0207509D0/en
Application filed by Aimsco Limited filed Critical Aimsco Limited
Publication of PL367828A1 publication Critical patent/PL367828A1/pl
Publication of PL216741B1 publication Critical patent/PL216741B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C07K16/1145—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C07K16/114—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • AIDS & HIV (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
PL367828A 2001-07-02 2002-07-02 Zastosowanie poliklonalnego koziego przeciwciała anty-HLA klasy II PL216741B1 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0116151A GB0116151D0 (en) 2001-07-02 2001-07-02 Therapeutic agent
GB0128638A GB0128638D0 (en) 2001-11-29 2001-11-29 Therapeutic agent
GBGB0201896.8A GB0201896D0 (en) 2002-01-28 2002-01-28 Treatment
GB0207509A GB0207509D0 (en) 2002-03-28 2002-03-28 Therapeutic agent

Publications (2)

Publication Number Publication Date
PL367828A1 true PL367828A1 (pl) 2005-03-07
PL216741B1 PL216741B1 (pl) 2014-05-30

Family

ID=27447968

Family Applications (1)

Application Number Title Priority Date Filing Date
PL367828A PL216741B1 (pl) 2001-07-02 2002-07-02 Zastosowanie poliklonalnego koziego przeciwciała anty-HLA klasy II

Country Status (18)

Country Link
US (4) US20100291102A1 (pl)
EP (1) EP1404367B1 (pl)
JP (2) JP5014562B2 (pl)
KR (2) KR20040030786A (pl)
CN (1) CN100423776C (pl)
AT (1) ATE478681T1 (pl)
AU (1) AU2002317285B2 (pl)
BR (1) BR0210772A (pl)
CA (1) CA2452986C (pl)
DE (1) DE60237447D1 (pl)
DK (1) DK1404367T3 (pl)
EA (1) EA013517B1 (pl)
HU (1) HU228957B1 (pl)
IL (2) IL159682A0 (pl)
MX (1) MXPA04000147A (pl)
NZ (1) NZ530393A (pl)
PL (1) PL216741B1 (pl)
WO (1) WO2003004049A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0201896D0 (en) * 2002-01-28 2002-03-13 Ice Biolog Ltd Treatment
IL159682A0 (en) * 2001-07-02 2004-06-20 Aimsco Ltd Use of polyclonal anti-hiv goat serum as a therapeutic agent
AU2003202093B2 (en) * 2001-07-02 2010-05-13 Aimsco Limited Treatment of MS with goat serum
BRPI0509629A (pt) 2004-04-05 2007-09-18 Aimsco Ltd método de tratar um distúrbio, composição farmacêutica, uso de uma composição, e, métodos de melhorar transmissões neurais em nervos danificados não-desmielinizados, e de restaurar transmissão neural nervos degenerados
GB0415359D0 (en) * 2004-07-08 2004-08-11 Aimsco Ltd Medicament
WO2006021814A2 (en) * 2004-07-08 2006-03-02 Aimsco Limited Medicament
GB0502083D0 (en) * 2005-02-02 2005-03-09 Aimsco Ltd Bioactive compounds
GB0508153D0 (en) * 2005-04-22 2005-06-01 Aimsco Ltd Therapeutic agent
GB0509052D0 (en) * 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
GB0600202D0 (en) * 2006-01-06 2006-02-15 Aimsco Ltd Treatment of HIV
EA200970271A1 (ru) * 2006-09-11 2010-02-26 Новартис Аг Получение вакцин против вируса гриппа без использования куриных эмбрионов
US8734852B2 (en) * 2011-11-30 2014-05-27 Manu Chaudhary Parenteral controlled release formulations of NSAID's
CA2877562A1 (en) 2012-06-25 2014-01-03 Aimsco Limited Formulation comprising crh and alpha-2 macroglobulin
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
MY193117A (en) 2017-01-31 2022-09-26 Illumina Inc Fluidic devices and methods of manufacturing the same
CN117538549A (zh) * 2023-09-27 2024-02-09 上海交通大学医学院附属瑞金医院 一种评估血浆置换清除dsa临床疗效的预测体系

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
JPH02237935A (ja) * 1989-03-10 1990-09-20 Bio Kagaku Kenkyusho:Kk エイズ処置剤
WO1996020215A2 (en) * 1994-12-23 1996-07-04 Laboratoires Om S.A. Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases
WO1996040941A1 (en) * 1995-06-07 1996-12-19 Connaught Laboratories Limited Chimeric antibodies for delivery of antigens to selected cells of the immune system
WO1997002839A1 (en) * 1995-07-13 1997-01-30 Gkc Research, Inc. Viral suppression, treatment and prevention of viral infections
US6448000B1 (en) * 1996-04-15 2002-09-10 Vanderbilt University Mammalian genes involved in viral infection and tumor suppression
GB9619894D0 (en) * 1996-09-24 1996-11-06 Celltech Therapeutics Ltd Pharmaceutical products
WO2000012560A1 (en) * 1998-08-28 2000-03-09 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
CA2270600A1 (en) * 1999-05-03 2000-11-03 Infectio Recherche Inc. Method and formulations for the treatment of diseases, particularly those caused by human immunodeficiency virus and leishmania
HK1042049A1 (en) * 1999-05-24 2002-08-02 Sankyo Company, Limited Medicinal compositions containing anti-fas antibody
DE05075555T1 (de) * 1999-06-09 2007-02-08 Immunomedics, Inc. Immuntherapie von Autoimmunerkrankungen durch die Verwendung von B-Zell-spezifischen Antikörpern
WO2001060156A1 (en) * 2000-02-14 2001-08-23 Gary R. Davis, M.D., L.L.C. Neutralizing antibody and immunomodulatory enhancing compositions
ATE365749T1 (de) * 2000-05-12 2007-07-15 Gpc Biotech Ag Humane peptide/proteine, die das töten von zellen,einschliesslich lymphoide tumorzellen, herbeiführen oder bewirken
EP1156062A1 (en) * 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
WO2002007760A2 (en) * 2000-07-21 2002-01-31 Ice Biologics Limited Therapeutic agent against aids comprising anti hiv goat antibody
IL159682A0 (en) * 2001-07-02 2004-06-20 Aimsco Ltd Use of polyclonal anti-hiv goat serum as a therapeutic agent

Also Published As

Publication number Publication date
WO2003004049A2 (en) 2003-01-16
WO2003004049A3 (en) 2003-04-24
CN1620311A (zh) 2005-05-25
EA013517B1 (ru) 2010-06-30
CA2452986C (en) 2011-11-01
US20100291102A1 (en) 2010-11-18
IL159682A0 (en) 2004-06-20
EP1404367B1 (en) 2010-08-25
KR20040030786A (ko) 2004-04-09
JP5014562B2 (ja) 2012-08-29
JP2009149693A (ja) 2009-07-09
BR0210772A (pt) 2004-07-20
JP5128539B2 (ja) 2013-01-23
US20130230600A1 (en) 2013-09-05
AU2002317285B2 (en) 2007-05-24
PL216741B1 (pl) 2014-05-30
DK1404367T3 (da) 2010-12-13
ATE478681T1 (de) 2010-09-15
IL221708A0 (en) 2012-10-31
JP2004536105A (ja) 2004-12-02
HUP0401392A2 (hu) 2004-10-28
CA2452986A1 (en) 2003-01-16
KR20090046970A (ko) 2009-05-11
HUP0401392A3 (en) 2012-09-28
NZ530393A (en) 2006-10-27
US20120100156A1 (en) 2012-04-26
MXPA04000147A (es) 2005-01-07
CN100423776C (zh) 2008-10-08
EP1404367A2 (en) 2004-04-07
US20160002320A1 (en) 2016-01-07
DE60237447D1 (de) 2010-10-07
KR100938590B1 (ko) 2010-01-26
HU228957B1 (en) 2013-07-29
IL221708A (en) 2013-12-31
EA200400134A1 (ru) 2004-08-26
HK1064936A1 (en) 2005-02-08

Similar Documents

Publication Publication Date Title
IL221708A0 (en) Polyclonal goat anti-hla class ii antibody for treatment of disease involving proliferative immune response
DK0771216T3 (da) Fremgangsmåder og præparater til specifik koagulering af tumorvaskulatur
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
DE60125797D1 (de) Impfstoffzusammesetzung
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
BR0108471A (pt) Objeto pré-formado para liberar um agente ativo a um paciente, e, processos de formação de um objeto pré-formado para liberar um agente e de liberação de um agente ativo a um paciente
NO20002785D0 (no) Adamantanderivater
NO20002786L (no) Adamantanderivater
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
EP0997152A4 (en) MEDICINE AGAINST LYMPHATIC TUMORS
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
DE60238555D1 (de) Parathormon-antikörper und damit zusammenhängende verfahren
AU6819600A (en) Use of cd28 specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections
EE200100366A (et) Antikehade kasutamine vähivastase farmatseutilisekompositsiooni valmistamiseks
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
DE60222296D1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
ATE338819T1 (de) Antigenes protein aus malassezia
DE60112768D1 (de) Behandlung von entzündlichen erkrankungen
ATE545421T1 (de) Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat
ATE324450T1 (de) Polypeptid, das neutralisierende antikörper gegen hiv induziert
AR027738A1 (es) Composicion coadyuvante, composiciones de vacunas que incluyen dicha composicion coadyuvante; procedimiento de induccion de inmunorespuestas antigenicas enmamiferos y procedimiento de tratamiento donde se aplican dichas vacunas
ZA916313B (en) New use of a monoclonal antibody
DE60333898D1 (de) Behandlung von krankheiten des nervensystems mit ziegenserum